



PTO/SB/08B (08-03)

Approved for use through 07/31/06. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/155,590
		Filing Date	September 30, 1998
		First Named Inventor	Jeffrey SCHLOM et al.
		Art Unit	1643
		Examiner Name	CANELLA, Karen A.
Sheet 1	of 2	Attorney Docket Number	38163-0061


NON PATENT LITERATURE DOCUMENTS			
Examiner initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAL	B01	Carbone DP, Ciernik IF, Kelley MJ et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 2005;23:5099-107.	
	B02	Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004;113:1515-25.	
	B03	Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401-11.	
	B04	Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65:8059-64.	
	B05	Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-75.	
	B06	Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.	

Examiner Signature	<i>Karen A. Canella</i>	Date Considered	5/15/06
-----------------------	-------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office.



PTO/SB/08B (08-03)

Approved for use through 07/31/06. OMB 0651-0031

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/155,590
		Filing Date	September 30, 1998
		First Named Inventor	Jeffrey SCHLOM et al.
		Art Unit	1643
		Examiner Name	CANELLA, Karen A.
(Use as many sheets as necessary)		Attorney Docket Number	38163-0061
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAC	B07	Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.	
	B08	Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.	
	B09	Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-89.	
	B10	Abrams SI, Hand PH, Tsang KY, Schlom J. Mutant ras epitopes as targets for cancer vaccines. Semin. Oncol. 1996;23:118-34.	
	B11	Fossum B, Gedde-Dahl I, T., Breivik J et al. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp). Int. J. Cancer 1994;56:40-5.	
	B12	Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA. Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol 2001;21:287-97.	
✓	B13	Linard B, Bezieau S, Benlalam H et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 2002;168:4802-8.	

Examiner Signature	<i>Karen A. Canella</i>	Date Considered	5/15/06
-----------------------	-------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public